{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T20:10:05Z","timestamp":1759695005620,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.mehy.2020.110150","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T21:57:36Z","timestamp":1596146256000},"page":"110150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content"],"prefix":"10.1016","volume":"143","author":[{"given":"Fatma","family":"Beyazit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yavuz","family":"Beyazit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpaslan","family":"Tanoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim C.","family":"Haznedaroglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.110150_b0005","first-page":"157","article-title":"WHO Declares COVID-19 a Pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed"},{"key":"10.1016\/j.mehy.2020.110150_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173326","article-title":"Drug treatment of coronavirus disease 2019 (COVID-19) in China","volume":"883","author":"Jin","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mehy.2020.110150_b0015","doi-asserted-by":"crossref","DOI":"10.4155\/fmc-2020-0158","article-title":"Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2","author":"Fan","year":"2020","journal-title":"Future Med Chem"},{"key":"10.1016\/j.mehy.2020.110150_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109957","article-title":"Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?","volume":"144","author":"Haggag","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2020.110150_b0025","doi-asserted-by":"crossref","DOI":"10.1177\/2050312120907811","article-title":"Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)","volume":"8","author":"Ciftciler","year":"2020","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.mehy.2020.110150_b0030","article-title":"Ankaferd hemostat: From molecules to medicine","author":"\u00c7ift\u00e7iler","year":"2020","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.mehy.2020.110150_b0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2011.10.006","article-title":"Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat","volume":"83","author":"Haznedaroglu","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.mehy.2020.110150_b0040","first-page":"329","article-title":"Evaluation of hemostatic effects of Ankaferd as an alternative medicine","volume":"15","author":"Beyazit","year":"2010","journal-title":"Altern Med Rev"},{"key":"10.1016\/j.mehy.2020.110150_b0045","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3906\/sag-1808-60","article-title":"Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study","volume":"49","author":"\u00c7ift\u00e7iler","year":"2019","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.mehy.2020.110150_b0050","first-page":"302","article-title":"On Being a \u201cPhysician Patient\u201d with His Own Experimental Therapeutic Drug","volume":"35","author":"\u00c7ift\u00e7iler","year":"2018","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.mehy.2020.110150_b0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3906\/sag-1807-206","article-title":"Effects of Ankaferd Hemostat on Helicobacter pylori strains and antibiotic resistance","volume":"49","author":"\u00c7ift\u00e7iler","year":"2019","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.mehy.2020.110150_b0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5578\/mb.4264","article-title":"In Vitro Effect of Ankaferd Blood Stopper (R), a Plant Extract Against Mycobacterium tuberculosis Isolates","volume":"47","author":"Deveci","year":"2013","journal-title":"Mikrobiyoloji Bulteni"},{"key":"10.1016\/j.mehy.2020.110150_b0065","doi-asserted-by":"crossref","DOI":"10.3906\/sag-2004-94","article-title":"Anti-infective and wound-healing pleiotropic actions of Ankaferd hemostat","author":"Haznedaro\u011flu","year":"2020","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.mehy.2020.110150_b0070","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.arbres.2013.12.007","article-title":"Effective management of hemoptysis via endobronchial application of Ankaferd hemostat","volume":"50","author":"Uzun","year":"2014","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.mehy.2020.110150_b0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.antiviral.2011.02.003","article-title":"Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB\/c mouse model by stinging nettle lectin, Urtica dioica agglutinin","volume":"90","author":"Kumaki","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.mehy.2020.110150_b0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4274\/tjh.2015.0073","article-title":"Antibacterial activities of ankaferd hemostat (ABS) on shiga toxin-producing escherichia coli and other pathogens significant in foodborne diseases","volume":"34","author":"Koluman","year":"2017","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.mehy.2020.110150_b0085","first-page":"198","article-title":"Antimicrobial activity of Ankaferd Blood Stopper\u00ae against nosocomial bacterial pathogens","volume":"5","author":"Saribas","year":"2010","journal-title":"Cent Eur J Med"},{"key":"10.1016\/j.mehy.2020.110150_b0090","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4999\/uhod.15811","article-title":"Safety and Efficacy of Ankaferd Hemostat (ABS) in the Chemotherapy-Induced Oral Mucositis","volume":"25","author":"Atay","year":"2015","journal-title":"Int J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110150_b0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4274\/tjh.2017.0320","article-title":"Effectiveness of Ankaferd BloodStopper in Prophylaxis and Treatment of Oral Mucositis in Childhood Cancers Evaluated with Plasma Citrulline Levels","volume":"35","author":"Pat\u0131ro\u011flu","year":"2018","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.mehy.2020.110150_b0100","doi-asserted-by":"crossref","DOI":"10.3906\/sag-2005-395","article-title":"The effects of blood group types on the risk of COVID-19 infection and its clinical outcome","author":"G\u00f6ker","year":"2020","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.mehy.2020.110150_b0105","doi-asserted-by":"crossref","DOI":"10.1177\/1470320320928872","article-title":"In vitro analysis of the renin-angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus","volume":"21","author":"Turk","year":"2020","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.mehy.2020.110150_b0110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5152\/tjh.2010.03","article-title":"Functional proteomic analysis of Ankaferd\u00ae Blood Stopper. Kanama durdurucu Ankaferd\u00ae ve etki mekanizmas\u0131n\u0131n proteomik analizi","volume":"27","author":"\u00d6zel Demiralp","year":"2010","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.mehy.2020.110150_b0115","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1177\/1076029617737838","article-title":"Ankaferd Influences mRNA Expression of Iron-Regulated Genes During Iron-Deficiency Anemia","volume":"24","author":"Gulec","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.mehy.2020.110150_b0120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/1076029609343706","article-title":"Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of Ankaferd Blood Stopper","volume":"16","author":"Haznedaroglu","year":"2010","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.mehy.2020.110150_b0125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5505\/tjh.2012.90277","article-title":"The Dual Diverse Dynamic Reversible Effects of Ankaferd Blood Stopper on EPCR and PAI-1 Inside Vascular Endothelial Cells With and Without LPS Challenge","volume":"29","author":"Karab\u0131y\u0131k","year":"2012","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.mehy.2020.110150_b0130","first-page":"276","article-title":"The effects of Ankaferd Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile","volume":"28","author":"Y\u0131lmaz","year":"2011","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.mehy.2020.110150_b0135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.mehy.2020.110150_b0140","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","article-title":"Considering how biological sex impacts immune responses and COVID-19 outcomes","volume":"20","author":"Scully","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.mehy.2020.110150_b0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4274\/tjh.2015.0143","article-title":"Endothelial cells, ankaferd hemostat, and estradiol. endotel h\u00fccreleri, ankaferd ve estradiol","volume":"33","author":"Ard\u0131\u00e7o\u011flu","year":"2016","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.mehy.2020.110150_b0150","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4999\/uhod.204171","article-title":"Local Bone Marrow Renin-Angiotensin System and COVID-19","volume":"30","author":"Ciftciler","year":"2020","journal-title":"Int J Hematol Oncol"},{"key":"10.1016\/j.mehy.2020.110150_b0155","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110150_b0160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fmed.2020.00301","article-title":"Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis","volume":"7","author":"Feng","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.mehy.2020.110150_b0165","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2213-2600(20)30216-2","article-title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation","volume":"8","author":"Jose","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.mehy.2020.110150_b0170","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mehy.2020.110150_b0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/ATVBAHA.118.311655","article-title":"Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases","volume":"39","author":"Posma","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.mehy.2020.110150_b0180","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/thoraxjnl-2013-204367","article-title":"Proteinase-activated receptors in fibroproliferative lung disease","volume":"69","author":"Jos\u00e9","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.mehy.2020.110150_b0185","doi-asserted-by":"crossref","first-page":"E165","DOI":"10.1177\/1076029610394437","article-title":"Reversible protease-activated receptor 1 downregulation mediated by Ankaferd blood stopper inducible with lipopolysaccharides inside the human umbilical vein endothelial cells","volume":"17","author":"Karabiyik","year":"2011","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.mehy.2020.110150_b0190","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fimmu.2015.00635","article-title":"The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases","volume":"6","author":"Khan","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.mehy.2020.110150_b0195","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.3390\/ijms150610116","article-title":"The role of AhR in autoimmune regulation and its potential as a therapeutic target against CD4 T cell mediated inflammatory disorder","volume":"15","author":"Zhu","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.mehy.2020.110150_b0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2042-6410-1-6","article-title":"Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17\u03b2-oestradiol-dependent and sex chromosome-independent","volume":"1","author":"Liu","year":"2010","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.mehy.2020.110150_b0205","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nature24265","article-title":"Landscape of X chromosome inactivation across human tissues","volume":"550","author":"Tukiainen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2020.110150_b0210","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000508076","article-title":"COVID-19: Possible Impact of the Genetic Background in IFNL Genes on Disease Outcomes","volume":"12","author":"Mihm","year":"2020","journal-title":"J Innate Immun."},{"key":"10.1016\/j.mehy.2020.110150_b0215","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2011-08-371831","article-title":"The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor \u03b1 signaling","volume":"119","author":"Seillet","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2020.110150_b0220","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.4049\/jimmunol.177.4.2088","article-title":"TLR7 ligands induce higher IFN-alpha production in females","volume":"177","author":"Bergh\u00f6fer","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2020.110150_b0225","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.gie.2014.10.007","article-title":"Severe radiation esophagitis successfully treated with Ankaferd hemostat","volume":"81","author":"Ozturk","year":"2015","journal-title":"Gastrointest Endosc."},{"key":"10.1016\/j.mehy.2020.110150_b0230","doi-asserted-by":"crossref","DOI":"10.1177\/2050312117722569","article-title":"Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper","volume":"5","author":"Simsek","year":"2017","journal-title":"SAGE Open Med."},{"issue":"65","key":"10.1016\/j.mehy.2020.110150_b0235","first-page":"183","article-title":"An immunohistochemistry and histopathological study of ankaferd blood stopper in a rat model of cervical inflammation","volume":"2019","author":"Beyazit","year":"1992","journal-title":"Rev Assoc Med Bras"},{"key":"10.1016\/j.mehy.2020.110150_b0240","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4274\/tjod.galenos.2018.21298","article-title":"The efficacy of Ankaferd Blood Stopper\u00ae in an experimental Asherman syndrome model created in rats","volume":"16","author":"B\u00fcy\u00fck","year":"2019","journal-title":"Turk J Obstet Gynecol"},{"key":"10.1016\/j.mehy.2020.110150_b0245","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.clinre.2011.02.013","article-title":"Percutaneous ankaferd injection to in vivo liver tissue in comparison to ethanol in an experimental rat model","volume":"35","author":"Ta\u015f","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.mehy.2020.110150_b0250","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.3748\/wjg.v17.i35.3962","article-title":"Ankaferd hemostat in the management of gastrointestinal hemorrhages","volume":"17","author":"Beyazit","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mehy.2020.110150_b0255","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4103\/1319-3767.111955","article-title":"Anti-inflammatory efficiency of Ankaferd blood stopper in experimental distal colitis model","volume":"19","author":"Ko\u00e7ak","year":"2013","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.mehy.2020.110150_b0260","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12974-019-1657-3","article-title":"Fibrinolysis protease receptors promote activation of astrocytes to express pro-inflammatory cytokines","volume":"16","author":"Pontecorvi","year":"2019","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.mehy.2020.110150_b0265","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fonc.2017.00261","article-title":"Tissue Factor-Expressing Tumor-Derived Extracellular Vesicles Activate Quiescent Endothelial Cells via Protease-Activated Receptor-1","volume":"7","author":"Che","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.mehy.2020.110150_b0270","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/1076029608319880","article-title":"The relation between cytokines, soluble endothelial protein C receptor, and factor VIII levels in Turkish pediatric stroke patients","volume":"15","author":"Y\u00fcr\u00fcrer","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.mehy.2020.110150_b0275","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1038\/s41598-018-33222-3","article-title":"PAR-1 is a novel mechano-sensor transducing laminar flow-mediated endothelial signaling","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.mehy.2020.110150_b0280","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1182\/blood-2010-06-293126","article-title":"Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis","volume":"116","author":"McEachron","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2020.110150_b0285","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1096\/fj.11-194704","article-title":"Regulation of human protease-activated receptor 1 (hPar1) gene expression in breast cancer by estrogen","volume":"26","author":"Salah","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.mehy.2020.110150_b0290","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/onc.2015.217","article-title":"Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2","volume":"35","author":"Yang","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.mehy.2020.110150_b0295","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/hmg\/ddt426","article-title":"A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis","volume":"23","author":"Chu","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.mehy.2020.110150_b0300","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1245\/s10434-011-1969-8","article-title":"The association of protease activated receptor 1 gene -506 I\/D polymorphism with disease-free survival in breast cancer patients","volume":"19","author":"Ero\u011flu","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.mehy.2020.110150_b0305","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.3390\/ijms19113451","article-title":"Transcriptional Landscape of PARs in Epithelial Malignancies","volume":"19","author":"Nag","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.mehy.2020.110150_b0310","doi-asserted-by":"crossref","DOI":"10.1111\/bph.15194","article-title":"Proteinase-activated receptor 1 (PAR1): A target for repurposing in the treatment of COVID-19?","author":"Sriram","year":"2020","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.mehy.2020.110150_b0315","first-page":"126","article-title":"A Placebo-Controlled, Randomized, Double-Blinded, Cross-Over Phase I Clinical Study To Demonstrate Safety of Ankaferd Blood Stopper Topical Usage In Healthy Volunteers","volume":"32","author":"Balcik","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.mehy.2020.110150_b0320","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.ijporl.2009.09.029","article-title":"Prospective, controlled clinical trial of Ankaferd Blood Stopper in children undergoing tonsillectomy","volume":"73","author":"Teker","year":"2009","journal-title":"Int J Pediatr Otorhinolaryngol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720321861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720321861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:32:08Z","timestamp":1759692728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720321861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":64,"alternative-id":["S0306987720321861"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110150","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110150"}}